BD Resumes U.S. Shipments of ChloraPrep After FDA Hold, PurPrep Still Paused
Becton, Dickinson and Company (BD) announced that it has lifted the shipping hold on its antiseptic product ChloraPrep™ in the United States, following additional final‑release testing that cleared the FDA warning letter concerns. The company’s other product, PurPrep™, remains on hold, underscoring ongoing remediation at BD’s El Paso manufacturing site.
Becton, Dickinson and Company (BDX) disclosed on May 29, 2026 that it has resumed U.S. shipments of ChloraPrep™ after a voluntary shipping hold imposed on May 6, 2026. The hold was triggered by an FDA Warning Letter directed at BD’s El Paso, Texas, manufacturing facility, which manufactures both ChloraPrep™ and PurPrep™ antiseptic solutions.
In response, BD performed extensive additional final‑release testing on the affected lots. The company said all test results were "acceptable" and that no patient safety signals were identified during the testing period. With those assurances, BD cleared ChloraPrep™ for distribution to ensure continuity of patient care across hospitals and clinics.
PurPrep™ remains on the shipping hold. The filing did not indicate a resumption date for the product, signaling that BD is still addressing the underlying issues cited in the FDA letter. Detailed information about the warning letter and the associated risk mitigation steps can be found in BD’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026.
The announcement arrived as BD’s stock traded modestly higher at $148.52, up 0.07% on the day, while the broader S&P 500 rose 0.27%. The share price has been under pressure this year, down 23.5% YTD, and sits near the lower end of its 52‑week range (about 10%). The limited price reaction suggests investors view the resumption of ChloraPrep™ shipments as a corrective step rather than a catalyst for immediate earnings growth.
The filing also contains the customary forward‑looking statements disclaimer, directing readers to BD’s latest Form 10‑K, Form 10‑Q, and other SEC filings for a fuller picture of the company’s outlook and risk factors.
Strategic implications: By quickly reinstating ChloraPrep™ shipments, BD aims to protect its market share in the antiseptic segment and avoid supply‑chain disruptions that could erode customer confidence. The continued hold on PurPrep™ highlights the importance of regulatory compliance and quality‑control investments for the company’s long‑term reputation.
Analysts will likely monitor BD’s next 10‑Q filing for updates on PurPrep™ and any additional remediation costs tied to the El Paso facility, as those factors could influence the company’s margin outlook and cash‑flow projections for the remainder of 2026.
Key Takeaways
- BD has resumed U.S. shipments of ChloraPrep™ after FDA‑related hold; PurPrep™ remains on hold.
- Additional final‑release testing showed acceptable results with no patient safety signals.
- The FDA Warning Letter pertains to BD’s El Paso manufacturing site; details are in the March 31, 2026 Form 10‑Q.
- Shares edged up 0.07% to $148.52, but remain down 23.5% YTD, reflecting broader market pressures.
- Forward‑looking statements are disclosed; investors should review BD’s latest 10‑K and 10‑Q for full context.